Pegcetacoplan combines a complement-targeting cyclic peptide with polyethylene glycol chains to modulate solubility and hydrodynamic radius. The PEGylated architecture decreases aggregation and can prolong circulation in model systems. Researchers examine its binding to complement components, conformational features, and complex formation. Applications include complement-pathway mechanism studies, ligand-protein interaction analysis, and bioconjugate-engineering work.
CAT No: R2736
CAS No:2019171-69-6
Synonyms/Alias:Pegcetacoplan; 2019171-69-6; TO3JYR3BOU; Syfovre; APL-2; APL 2; APL-2 peptide; APL2; O,O'-BIS((S2,S12-CYCLO(N-ACETYL-L-ISOLEUCYL-L-CYSTEINYL-L-VALYL-1-METHYL-L-TRYPTOPHYL-L-GLUTAMINYL-L-alpha-ASPARTYL-L-TRYPTOPHYLGLYCYL-L-ALANYL-L-HISTIDYL-L-ARGINYL-L-CYSTEINYL-L-THREONYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-L-LYSINAMIDE))-N6.15-CARBONYL)POLYETHYLENE GLYCOL (N = 800-1100); POLY(OXY-1,2-ETHANEDIYL), alpha-HYDRO-omega-HYDROXY-, 15,15'-DIESTER WITH N-ACETYL-L-ISOLEUCYL-L-CYSTEINYL-L-VALYL-1-METHYL-L-TRYPTOPHYL-L-GLUTAMINYL-L-alpha-ASPARTYL-L-TRYPTOPHYLGLYCYL-L-ALANYL-L-HISTIDYL-L-ARGINYL-L-CYSTEINYL-L-THREONYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-N6-CARBOXY-L-LYSINAMIDE CYCLIC (2->12)-(DISULFIDE); UNII-TO3JYR3BOU; pegcetacoplanum
Pegcetacoplan is a synthetic, pegylated cyclic peptide designed to function as a targeted inhibitor of the complement protein C3. As a complement inhibitor, it plays a crucial role in modulating the activity of the innate immune system by binding and regulating the central component of the complement cascade. Its unique structure, which incorporates both peptide and polyethylene glycol (PEG) elements, confers enhanced stability and extended biological activity, making it a valuable tool for researchers investigating complement-mediated processes. The compound's ability to precisely modulate complement activation has positioned it as an essential reagent in the study of immune regulation, inflammation, and related biochemical pathways.
Complement system research: Pegcetacoplan serves as a precise molecular probe for dissecting the mechanisms underlying complement activation and regulation. By specifically binding to complement protein C3 and inhibiting its cleavage, the compound enables researchers to study the downstream effects of complement blockade in vitro and in ex vivo models. Its application facilitates detailed analysis of the roles played by C3 in immune surveillance, inflammation, and cellular homeostasis, allowing for the elucidation of complex interactions within the innate immune system.
Inflammation pathway studies: The ability of pegcetacoplan to suppress complement-driven inflammatory responses makes it a valuable agent for exploring the molecular basis of inflammation. Researchers utilize it to model complement-mediated tissue injury, analyze the contribution of C3 activation to cytokine release, and investigate the interplay between complement and other inflammatory mediators. These studies provide insights into the pathophysiology of immune-mediated disorders and help define the critical checkpoints within inflammatory signaling cascades.
Protein interaction analysis: As a selective C3 inhibitor, pegcetacoplan is instrumental in mapping protein-protein interactions within the complement cascade. Its use in biochemical assays allows for the characterization of binding affinities, conformational changes, and the identification of novel interaction partners. Such studies are essential for understanding the structural dynamics of complement components and for identifying potential regulatory nodes within the pathway.
Immunological assay development: The compound's specificity and robust inhibitory profile make it an ideal standard or control in the development of immunoassays aimed at detecting complement activity or dysfunction. By providing a well-characterized means of modulating C3 activity, it supports the validation of assay sensitivity and specificity, contributing to the advancement of reliable analytical tools for complement research.
Drug discovery and screening: Pegcetacoplan is widely employed in preclinical research as a reference inhibitor in high-throughput screening platforms and mechanistic studies. Its defined mode of action and reproducible effects on complement activity enable researchers to benchmark new small molecules, peptides, or biologics targeting the complement system. This application is particularly valuable for identifying and optimizing novel modulators of C3 and related pathway components, accelerating the development of next-generation complement inhibitors for research use.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More